Singapore, Oct 31, 2006: The primary factors pharmaceutical and biotech companies consider when selecting a CRO are the strength of its scientific expertise and the cost/value ratio associated with the study, according to a report released at the annual meeting of the American Association of Pharmaceutical Scientists.

The study, commissioned by Delaware-based Quest Pharmaceutical Services (QPS) and conducted by SCORR Marketing with industry experts, indicates that companies engaged in preclinical development are most interested in a CRO with demonstrated scientific knowledge and technical skills, as well as one that offers good value for its expertise and service.

Secondary considerations include the CRO's timeliness in scheduling, meeting timelines, and executing overall turnaround, as well as its responsiveness in communicating with scientific personnel, business development and project managers.

CRO decision-makers clearly articulated the importance of service quality, priority setting and the ability for rapid, effective problem-solving in service provider selection.

Other important CRO attributes include resources to handle the job, location of laboratories, quality of reports, flexibility as study progresses, and history of prior relationship.

Mr Ben Chien, President and CEO of QPS said, “It's crucial to QPS that we have a clear picture of what is important to our current and future clients, which is why we undertook this study. And knowing our clients' perceptions, preferences, and habits enhances our ability to meet their evolving needs and to earn us consideration when they are making their outsourcing decisions."